Date: 2014-12-04
Type of information: Licensing agreement
Compound: CRISPR-Cas9 gene engineering system
Company: GE Healthcare (USA - WI) Broad Institute of MIT and Harvard (USA - MA)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On December 4, 2014, GE Healthcare Life Sciences, the Broad Institute of MIT and Harvard announced the signing of a non-exclusive license agreement granting GE Healthcare Life Sciences access to intellectual property held by the Broad Institute relating to the CRISPR-Cas9 gene engineering system for research purposes. The CRISPR-Cas9 system allows scientists to modify gene expression in order to gain insights vital to the understanding of disease. The intellectual property license from the Broad Institute includes the first granted patent for the use of CRISPR technology in eukaryotic cells and is based on work described in Broad Institute core member Dr. Feng Zhang’s 2013 Science paper. In October 2014, GE Healthcare Life Sciences launched Dharmacon Edit-R Gene Engineering System, its CRISPR-Cas9-based platform for creating permanent and heritable gene knockouts in cells in one-to-two weeks versus the previous one-month timescale. The license granted by Broad will enable further platform development by incorporating the patented technologies and the launch of additional, complementary gene editing tools for the scientific community.
Financial terms:
Latest news:
